Related Experiment Video
Updated: Jun 5, 2025
12:58
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
8.9K
Anti-Interleukin-23 Treatment Linked to Improved Clostridioides difficile Infection Survival.
Medrxiv : the Preprint Server for Health Sciences
|December 16, 2024
Summary
Anti-interleukin-23 (anti-IL-23) therapy shows promise for treating Clostridioides difficile infection. Patients receiving anti-IL-23 had significantly lower mortality rates compared to controls, suggesting its potential as an adjunct treatment.
Area of Science:
- Immunology
- Infectious Diseases
- Pharmacology
Background:
- Clostridioides difficile infection (CDI) is a major cause of hospital-acquired infections with high mortality.
- Conventional antibiotic treatments for CDI are often insufficient, leading to a need for alternative therapies.
- Host-directed immunotherapy, particularly targeting pro-inflammatory pathways, is a promising strategy for CDI.
Purpose of the Study:
- To investigate the efficacy of anti-interleukin-23 (anti-IL-23) treatment in improving survival rates for hospitalized patients with CDI.
- To evaluate if IL-23 inhibition, a known therapy for autoimmune conditions, could be repurposed for CDI treatment.
Main Methods:
- A retrospective analysis of a large electronic health record database was conducted.
- The study compared survival outcomes of 9,301 hospitalized CDI patients treated with anti-IL-23 agents to propensity-matched controls.
- Statistical analysis focused on all-cause mortality within 30 days of treatment.
Main Results:
- Patients receiving anti-IL-23 treatment exhibited a significantly lower probability of all-cause death within 30 days (0.54%) compared to control patients (3.1%).
- This represents a substantial survival benefit associated with IL-23 inhibition in CDI patients.
Conclusions:
- IL-23 inhibition demonstrates potential as an effective adjunct therapy for managing Clostridioides difficile infection.
- Further clinical trials are warranted to confirm the efficacy of repositioning anti-IL-23 monoclonal antibodies for CDI treatment.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
115
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
115
01:29Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
01:29Inflammatory Bowel Disease IV: Pharmacological Management
111
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
111
01:17Drugs for Treatment of Diarrhea-Predominant IBS
147
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
147